da Super User | Ott 22, 2019 | Recommended events
Oct. 22-23, 2019New York, USA
da Super User | Ott 22, 2019 | Eventi consigliati
22-23 Ott., 2019New York, USA
da Luca Bonadei | Ott 22, 2019 | Business
https://www.statnews.com Zolgensma is Novartis’ lifesaving gene therapy treatment for infants with spinal muscular atrophy, a rare and devastating neurological disease. Zolgensma has been used to treat 100 patients since its launch and brought in $160 million last...
da Luca Bonadei | Ott 22, 2019 | Business
https://www.statnews.com Zolgensma è la terapia genica salvavita di Novartis per i bambini con atrofia muscolare spinale, una malattia neurologica rara e devastante. Zolgensma è stato usato per trattare 100 pazienti dal suo lancio e ha portato $ 160 milioni...
da Luca Bonadei | Lug 22, 2019 | Regulatory
https://www.prweb.com Personalized Stem Cells, a human adipose-derived stem cell company, has received FDA approval for their Investigational New Drug application to use a person’s own adipose-derived stem cells to treat their osteoarthritis; the first clinical trial,...